The Latest Cardiac and Vascular News
Up to 25% of advanced heart failure patients suffer from pulmonary hypertension Aeson® could potentially become a standard treatment for these thousands of patients, both as a bridge-to-transplant and destination therapy February 17, 2025 01:00 AM Eastern Standard Time PARIS–(BUSINESS WIRE)–Regulatory News: “In our experience with patients suffering from pulmonary […]
PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today announces that it has passed the milestone of 100 implants of its Aeson® artificial […]
Over 90 patients have received the Aeson® artificial heart since the first implant in 2013, including 42 in 2024. 2024 Sales of €7 million (a 2.5-fold increase vs 2023). Cash burn reduced by over 20% vs 2023. 50 hospitals trained in Aeson® implants internationally1. Successful first “Aeson® User Meeting” and […]
Buy-back by CARMAT of 2 million shares from Airbus for a symbolic sum of 1 euro. The shares so bought-back will be allocated to the repayment of the Company’s financial debt, via their use in the ongoing equitization of the loan contracted with the European Investment Bank, thus reducing the […]
This capital increase will be carried out through a public offering without preferential subscription rights and with a 7 trading days priority period, on an irreducible and reducible basis, for the benefit of CARMAT’s shareholders The initial amount of the capital increase may be increased up to €11.8 million in […]
Half-year sales of €3.3 million, exceeding 2023 full-year sales 20 implants of the Aeson® artificial heart performed in the first half of 2024 17% cash-burn1 reduction compared to the first half of 2023 2024 anticipated annual sales of €8 to €12 million Other 2024 operational objectives on track Active exploration of […]
20 implants of the Aeson® artificial heart performed in the first half of 2024 Pace of 4 implants per month in the second quarter Half-year sales at €3.2 million, higher than the 2023 full-year sales Unique safety and performance profile of Aeson® confirmed, based on more than 70 implants made since inception […]
June 13, 2024 12:00 PM Eastern Daylight Time PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (Paris:ALCAR): On February 14, 2023, the French financial markets authority (Autorité des marchés financiers) invited companies issuing equity securities or securities giving access to capital on a staggered basis to adopt a standard communication and warning on the […]
PARIS–(BUSINESS WIRE)–Regulatory News: “I’m very pleased with the progress of the EFICAS study, both in terms of the pace of inclusion and results observed to date. ” Post this CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for […]
PARIS–(BUSINESS WIRE)–Regulatory News: “Plan de Relance pour l’industrie – Secteurs Stratégiques” Post this CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today reports its annual results […]
